The protein tyrosine phosphatase receptor type R gene is an early and frequent target of silencing in human colorectal tumorigenesis

Molecular Cancer

Volumn 8, Issue , 2009, Pages

  Menigatti, Mirco ^a   Cattaneo, Elisa ^a   Sabates Bellver, Jacob ^a   Ilinsky, Valery V ^a   Went, Philip ^b   Buffoli, Federico ^c   Marquez, Victor E ^d   Jiricny, Josef ^a   Marra, Giancarlo ^a  

^a UNIVERSITY OF ZURICH   (Switzerland)

^b TRIEMLI HOSPITAL   (Switzerland)

^c Gastroenterology Unit   (Italy)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PROTEIN TYROSINE PHOSPHATASE RECEPTOR R; RECEPTOR; UNCLASSIFIED DRUG; MESSENGER RNA; PTPRR PROTEIN, HUMAN; RECEPTOR LIKE PROTEIN TYROSINE PHOSPHATASE;

ARTICLE; CANCER CELL CULTURE; CANCER SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; COLON ADENOCARCINOMA; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; GENE EXPRESSION; GENE IDENTIFICATION; GENE SILENCING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER METASTASIS; PRECANCER; RECTUM CARCINOMA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSCRIPTION INITIATION SITE; WESTERN BLOTTING; ADENOCARCINOMA; COLORECTAL TUMOR; GENETICS; PATHOLOGY;

ADENOCARCINOMA; COLORECTAL NEOPLASMS; DNA METHYLATION; GENE SILENCING; HUMANS; RECEPTOR-LIKE PROTEIN TYROSINE PHOSPHATASES, CLASS 7; RNA, MESSENGER;

EID: 74049138706     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-8-124     Document Type: Article

References (51)

1. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358:1148-1159. 10.1056/NEJMra072067, 18337604.
2. Jones PA, Baylin SB. The epigenomics of cancer. Cell 2007, 128:683-692. 10.1016/j.cell.2007.01.029, 17320506.
3. Merlo LM, Pepper JW, Reid BJ, Maley CC. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006, 6:924-935. 10.1038/nrc2013, 17109012.
4. Sabates-Bellver J, Flier LG, de Palo M, Cattaneo E, Maake C, Rehrauer H, Laczko E, Kurowski MA, Bujnicki JM, Menigatti M. Transcriptome profile of human colorectal adenomas. Mol Cancer Res 2007, 5:1263-1275. 10.1158/1541-7786.MCR-07-0267, 18171984.
5. Alonso A, Sasin J, Bottini N, Friedberg I, Osterman A, Godzik A, Hunter T, Dixon J, Mustelin T. Protein tyrosine phosphatases in the human genome. Cell 2004, 117:699-711. 10.1016/j.cell.2004.05.018, 15186772.
6. Hunter T. A thousand and one protein kinases. Cell 1987, 50:823-829. 10.1016/0092-8674(87)90509-5, 3113737.
7. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365. 10.1038/35077225, 11357143.
8. Hendriks WJ, Elson A, Harroch S, Stoker AW. Protein tyrosine phosphatases: functional inferences from mouse models and human diseases. FEBS J 2008, 275:816-830. 10.1111/j.1742-4658.2008.06249.x, 18298790.
9. Tonks NK. Protein tyrosine phosphatases: from genes, to function, to disease. Nat Rev Mol Cell Biol 2006, 7:833-846. 10.1038/nrm2039, 17057753.
10. Garcia JM, Silva J, Pena C, Garcia V, Rodriguez R, Cruz MA, Cantos B, Provencio M, Espana P, Bonilla F. Promoter methylation of the PTEN gene is a common molecular change in breast cancer. Genes Chromosomes Cancer 2004, 41:117-124. 10.1002/gcc.20062, 15287024.
11. Motiwala T, Ghoshal K, Das A, Majumder S, Weichenhan D, Wu YZ, Holman K, James SJ, Jacob ST, Plass C. Suppression of the protein tyrosine phosphatase receptor type O gene (PTPRO) by methylation in hepatocellular carcinomas. Oncogene 2003, 22:6319-6331. 10.1038/sj.onc.1206750, 14508512.
12. Oka T, Ouchida M, Koyama M, Ogama Y, Takada S, Nakatani Y, Tanaka T, Yoshino T, Hayashi K, Ohara N. Gene silencing of the tyrosine phosphatase SHP1 gene by aberrant methylation in leukemias/lymphomas. Cancer Res 2002, 62:6390-6394.
13. Xu S, Furukawa T, Kanai N, Sunamura M, Horii A. Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J Hum Genet 2005, 50:159-167. 10.1007/s10038-005-0235-y, 15824892.
14. Wang Z, Shen D, Parsons DW, Bardelli A, Sager J, Szabo S, Ptak J, Silliman N, Peters BA, Heijden MS. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004, 304:1164-1166. 10.1126/science.1096096, 15155950.
15. Ostman A, Hellberg C, Bohmer FD. Protein-tyrosine phosphatases and cancer. Nat Rev Cancer 2006, 6:307-320. 10.1038/nrc1837, 16557282.
16. Augustine KA, Silbiger SM, Bucay N, Ulias L, Boynton A, Trebasky LD, Medlock ES. Protein tyrosine phosphatase (PC12, Br7, S1) family: expression characterization in the adult human and mouse. Anat Rec 2000, 258:221-234. 10.1002/(SICI)1097-0185(20000301)258:3<221::AID-AR1>3.0.CO;2-W, 10705342.
17. Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL, Karuturi RK, Tan PB, Liu ET, Yu Q. Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 2007, 21:1050-1063. 10.1101/gad.1524107, 1855231, 17437993.
18. Kirmizis A, Bartley SM, Kuzmichev A, Margueron R, Reinberg D, Green R, Farnham PJ. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev 2004, 18:1592-1605. 10.1101/gad.1200204, 443521, 15231737.
19. Hendriks WJ, Dilaver G, Noordman YE, Kremer B, Fransen JA. PTPRR protein tyrosine phosphatase isoforms and locomotion of vesicles and mice. Cerebellum 2009, 8:80-88. 10.1007/s12311-008-0088-y, 2694922, 19137382.
20. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev 2002, 16:2893-2905. 10.1101/gad.1035902, 187479, 12435631.
21. Plath K, Fang J, Mlynarczyk-Evans SK, Cao R, Worringer KA, Wang H, de la Cruz CC, Otte AP, Panning B, Zhang Y. Role of histone H3 lysine 27 methylation in X inactivation. Science 2003, 300:131-135. 10.1126/science.1084274, 12649488.
22. Lindroth AM, Park YJ, McLean CM, Dokshin GA, Persson JM, Herman H, Pasini D, Miro X, Donohoe ME, Lee JT. Antagonism between DNA and H3K27 methylation at the imprinted Rasgrf1 locus. PLoS Genet 2008, 4:e1000145. 10.1371/journal.pgen.1000145, 2475503, 18670629.
23. Jepsen K, Solum D, Zhou T, McEvilly RJ, Kim HJ, Glass CK, Hermanson O, Rosenfeld MG. SMRT-mediated repression of an H3K27 demethylase in progression from neural stem cell to neuron. Nature 2007, 450:415-419. 10.1038/nature06270, 17928865.
24. Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J, Eden E, Yakhini Z, Ben-Shushan E, Reubinoff BE. Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 2007, 39:232-236. 10.1038/ng1950, 17200670.
25. Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM. The Polycomb group protein EZH2 directly controls DNA methylation. Nature 2006, 439:871-874. 10.1038/nature04431, 16357870.
26. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, Kelly TK, Marquez VE, Jones PA. DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation. Mol Cancer Ther 2009, 8:1579-1588. 10.1158/1535-7163.MCT-09-0013, 19509260.
27. Jones PL, Veenstra GJ, Wade PA, Vermaak D, Kass SU, Landsberger N, Strouboulis J, Wolffe AP. Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat Genet 1998, 19:187-191. 10.1038/561, 9620779.
28. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998, 393:386-389. 10.1038/30764, 9620804.
29. Eswaran J, von Kries JP, Marsden B, Longman E, Debreczeni JE, Ugochukwu E, Turnbull A, Lee WH, Knapp S, Barr AJ. Crystal structures and inhibitor identification for PTPN5, PTPRR and PTPN7: a family of human MAPK-specific protein tyrosine phosphatases. Biochem J 2006, 395:483-491. 10.1042/BJ20051931, 1462698, 16441242.
30. Buschbeck M, Eickhoff J, Sommer MN, Ullrich A. Phosphotyrosine-specific phosphatase PTP-SL regulates the ERK5 signaling pathway. J Biol Chem 2002, 277:29503-29509. 10.1074/jbc.M202149200, 12042304.
31. Munoz JJ, Tarrega C, Blanco-Aparicio C, Pulido R. Differential interaction of the tyrosine phosphatases PTP-SL, STEP and HePTP with the mitogen-activated protein kinases ERK1/2 and p38alpha is determined by a kinase specificity sequence and influenced by reducing agents. Biochem J 2003, 372:193-201. 10.1042/BJ20021941, 1223371, 12583813.
32. Ogata M, Oh-hora M, Kosugi A, Hamaoka T. Inactivation of mitogen-activated protein kinases by a mammalian tyrosine-specific phosphatase, PTPBR7. Biochem Biophys Res Commun 1999, 256:52-56. 10.1006/bbrc.1999.0278, 10066421.
33. Pulido R, Zuniga A, Ullrich A. PTP-SL and STEP protein tyrosine phosphatases regulate the activation of the extracellular signal-regulated kinases ERK1 and ERK2 by association through a kinase interaction motif. EMBO J 1998, 17:7337-7350. 10.1093/emboj/17.24.7337, 1171079, 9857190.
34. Chirivi RG, Noordman YE, Zee CE, Hendriks WJ. Altered MAP kinase phosphorylation and impaired motor coordination in PTPRR deficient mice. J Neurochem 2007, 101:829-840. 10.1111/j.1471-4159.2006.04398.x, 17266727.
35. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 2009, 16:368-377. 10.1038/cdd.2008.148, 18846109.
36. Sodir NM, Chen X, Park R, Nickel AE, Conti PS, Moats R, Bading JR, Shibata D, Laird PW. Smad3 deficiency promotes tumorigenesis in the distal colon of ApcMin/+ mice. Cancer Res 2006, 66:8430-8438. 10.1158/0008-5472.CAN-06-1437, 16951153.
37. Weyden L, Arends MJ, Dovey OM, Harrison HL, Lefebvre G, Conte N, Gergely FV, Bradley A, Adams DJ. Loss of Rassf1a cooperates with Apc(Min) to accelerate intestinal tumourigenesis. Oncogene 2008, 27:4503-4508. 10.1038/onc.2008.94, 18391979.
38. Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, Rosty C, Abal M, El Marjou F, Smits R. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 2006, 131:1096-1109. 10.1053/j.gastro.2006.08.011, 17030180.
39. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction?. Nat Rev Cancer 2006, 6:107-116. 10.1038/nrc1799, 16491070.
40. Feinberg AP, Ohlsson R, Henikoff S. The epigenetic progenitor origin of human cancer. Nat Rev Genet 2006, 7:21-33. 10.1038/nrg1748, 16369569.
41. Suzuki H, Watkins DN, Jair KW, Schuebel KE, Markowitz SD, Chen WD, Pretlow TP, Yang B, Akiyama Y, Van Engeland M. Epigenetic inactivation of SFRP genes allows constitutive WNT signaling in colorectal cancer. Nat Genet 2004, 36:417-422. 10.1038/ng1330, 15034581.
42. Flier LG, Sabates-Bellver J, Oving I, Haegebarth A, De Palo M, Anti M, Van Gijn ME, Suijkerbuijk S, Wetering M, Marra G, Clevers H. The Intestinal Wnt/TCF Signature. Gastroenterology 2007, 132:628-632. 10.1053/j.gastro.2006.08.039, 17320548.
43. Aliaga JC, Deschenes C, Beaulieu JF, Calvo EL, Rivard N. Requirement of the MAP kinase cascade for cell cycle progression and differentiation of human intestinal cells. Am J Physiol 1999, 277:G631-641.
44. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, Shimada Y, Ari-i S, Wada H, Fujimoto J, Kohno M. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999, 18:813-822. 10.1038/sj.onc.1202367, 9989833.
45. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. 10.1038/nature00766, 12068308.
46. Malumbres M, Barbacid M. RAS oncogenes: the first 30 years. Nat Rev Cancer 2003, 3:459-465. 10.1038/nrc1097, 12778136.
47. Rajagopalan H, Bardelli A, Lengauer C, Kinzler KW, Vogelstein B, Velculescu VE. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002, 418:934. 10.1038/418934a, 12198537.
48. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45. 10.1093/nar/29.9.e45, 55695, 11328886.
49. Menigatti M, Truninger K, Gebbers JO, Marbet U, Marra G, Schar P. Normal colorectal mucosa exhibits sex- and segment-specific susceptibility to DNA methylation at the hMLH1 and MGMT promoters. Oncogene 2009, 28:899-909. 10.1038/onc.2008.444, 19060925.
50. Fujimoto K, Beauchamp RD, Whitehead RH. Identification and isolation of candidate human colonic clonogenic cells based on cell surface integrin expression. Gastroenterology 2002, 123:1941-1948. 10.1053/gast.2002.37065, 12454851.
51. Marra G, D'Atri S, Corti C, Bonmassar L, Cattaruzza MS, Schweizer P, Heinimann K, Bartosova Z, Nystrom-Lahti M, Jiricny J. Tolerance of human MSH2 +/- lymphoblastoid cells to the methylating agent temozolomide. Proc Natl Acad Sci USA 2001, 98:7164-7169. 10.1073/pnas.121136498, 34640, 11416201.